STOCK TITAN
  1. Home
  2. Sec-filings
  3. ESLA
  4. [EFFECT] Estrella Immunopharma, Inc. SEC Filing

[EFFECT] Estrella Immunopharma, Inc. SEC Filing

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
EFFECT

Rhea-AI Filing Summary

Analyzing...
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Notice of Effectiveness
Effectiveness Date: January 23, 2026 4:00 P.M.
Form: S-1
CIK: 0001844417
Company Name: Estrella Immunopharma, Inc.
File Number: 333-292331

Source: View Original Filing on SEC EDGAR

Stock ESLA logo
Estrella Immunopharma

NASDAQ:ESLA

ESLA Rankings

#5691 Ranked by Market Cap
N/A Ranked by Dividends

ESLA Latest News

Jan 6, 2026
Estrella Immunopharma Announces Closing of $8.0 Million Registered Direct Offering and Concurrent Private Placement
Jan 5, 2026
Estrella Immunopharma, Inc. Announces $8.0 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules
Dec 4, 2025
Estrella Advances STARLIGHT-1 Trial into Phase II Following Positive DSMB Recommendation
Nov 3, 2025
Estrella Immunopharma Completes Second Dose Cohort in STARLIGHT-1 Trial of EB103 with Complete Responses in All Evaluable Patients
Oct 6, 2025
Estrella Immunopharma Regains Compliance with Nasdaq Listing Requirements

ESLA Latest SEC Filings

Jan 21, 2026
[S-1/A] Estrella Immunopharma, Inc. Amends IPO Registration Statement
Jan 16, 2026
[S-1/A] Estrella Immunopharma, Inc. Amends IPO Registration Statement
Jan 6, 2026
[8-K] Estrella Immunopharma, Inc. Reports Material Event
Jan 13, 2026
[8-K] Estrella Immunopharma, Inc. Reports Material Event
Nov 6, 2025
[8-K] Estrella Immunopharma, Inc. Reports Material Event

ESLA Stock Data

40.41M
11.69M
70.36%
1.71%
0.32%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
EMERYVILLE